Multidrug resistance-related proteins (MRPs) 2, 3 and 5 are involved in the efflux of drugs used in acute lymphoblastic leukemia (ALL) treatment. Polymorphisms of these genes were investigated for an association with treatment responses in 273 childhood ALL patients. The MRP3 AÀ189 allele of the regulatory AT polymorphism was associated with reduced event-free survival (P ¼ 0.01). The results remained significant after adjustment for multiple comparisons and in the multivariate analysis. Among patients with an event, the AÀ189 carriers had significantly higher methotrexate plasma levels (P ¼ 0.03). MRP3 AÀ189 also conferred four times higher risk of a relapse in central nervous system (P ¼ 0.01). Patients with this allele tended to have lower frequency of thrombocytopenia grade 2 (P ¼ 0.06). Gene reporter assay showed that the haplotype tagged by the AÀ189 had higher promoter activity (Pp0.01). In conclusion, MRP3 AÀ189 T polymorphism was associated with treatment responses in ALL, likely due to the change in MRP3 efflux.
Introduction
Owing to the introduction of effective combination risk-adapted therapies along with the prevention of central nervous system (CNS) disease, the treatment of pediatric acute lymphoblastic leukemia (ALL) has greatly improved in the past four decades. 1, 2 Nevertheless, therapy resistance in a significant number of children 3 is a major obstacle to successful treatment whereas intensive treatment has also important drug side effects. Genetic variations may explain, at least in part, differences in individual predisposition to respond to the treatment. Pharmacogenetic studies that have been conducted in ALL patients identified genetic variations in several drug pathways that may contribute to variability in treatment responses. 1, 4 Bioavailability of drugs used to treat ALL depends, among other factors, on the activity and expression of multidrug resistance-related proteins (MRPs or transporters of the adenosine triphosphate-binding cassette subfamily C). 5, 6 MRPs are expressed in the membranes of many barrier tissues contributing thus to plasma, liquor and intracellular drug disposition. 7, 8 MRPs were shown to bind and transport methotrexate (MTX), a key component of ALL treatment. 5, [9] [10] [11] [12] [13] [14] The increase in the MRP expression, as shown in vitro may lead to lower cellular MTX accumulation conferring moderate to high level of resistance. 5 Additionally, the capacity of MRPs to transport naturale folates and leucovorin may reduce the level of these compounds and thereby indirectly influence antifolate cytotoxicity. 5, 9 MRPs were also shown to efflux 6-mercaptopurine, vincristine and doxorubicin equally used in ALL treatment protocols. 15 As expression and function of MRP exhibit a broad variability, it was hypothesized that constitutive variations in the MRP genes could contribute to the variability in pharmacokinetics and/or clinical outcomes. 7 We recently showed that the polymorphisms of MRP4 gene can affect the risk of relapse and treatmentrelated toxicity in patients with ALL. 16 Here, we report the analysis of the polymorphisms in MRP 2, 3 and 5 genes, their association with ALL disease outcomes and treatmentrelated toxicity, as well as functional assessment of MRP3 polymorphism that we found to significantly affect treatment responses in ALL.
Patients and methods

Study population and endpoints in the analysis
The children enrolled in the study are 273 Caucasians (97.5% of patients were of French-Canadian origin from the similar geographical region) diagnosed with ALL at the Hospital Sainte-Justine, Montreal, Canada, between January 1989 and December 2003. The patients underwent treatment with the Dana-Farber Cancer Institute ALL Consortium protocols DFCI 87-01, 91-01, 95-01 or 2000-01. [17] [18] [19] The respective numbers of patients treated with these protocols were 12, 60, 121 and 80. The doses of MTX received were comparable across treatment protocols. On protocol 87-01, patients were randomized to receive an induction dose of MTX as either low-dose or high-dose (HD, 4 gm m -2 , followed by leucovorin rescue). 20 Only patients that received HD-MTX were included in this study. On protocols 91-01, 95-01 and 2000-01 a single HD-MTX was given during induction. In all protocols patients received once weekly doses of 30 mg m -2 during the consolidation (standard-risk patients) and maintenance (all patients) phases. CNS system directed treatment 20 was composed of intrathecal therapy (IT) with or without cranial radiation therapy (CRT). Patients that were assigned to standard (SR) risk on protocol 87-01 received IT without radiation. SR-girls on 91-01 protocol were treated with IT only. SR boys on 95-01 protocol were randomized to receive either more frequent IT alone or combined with CRT. On 2000-01, all SR patients received more frequent IT without CRT. IT treatment was composed of MTX/cytarabine in 87-01 and 91-01 protocols and in 95-01 and 2000-01 it was composed of MTX/cytarabine/hydrocortisone for patients receiving IT only. 20 IT dosing were according to age and IT MTX dose ranged from 6 to 12 mg. 19 Patient samples were obtained after informed consent and Hospital Ethics Committee approved the study protocol.
Association of genotypes with ALL outcomes was assessed by event-free survival (EFS), disease-free survival and overall survival analysis as previously described. 16 Children who relapsed, had an induction failure or died were defined to have had an event and children who relapsed or had induction failure were defined to have had a disease. Toxicity on bone marrow and liver function was based on the results of weekly laboratory tests collected during consolidation and maintenance treatment, as previously described. 21 The mean number of weeks assessed per patient was 80. Toxicity was graded using the common criteria for adverse events of National Cancer Institute and the frequency of the toxic events was estimated for each patient. 21 The toxicity data were available for 174 patients who were assessed for the relationship between genotypes and EFS probabilities. In order to regulate the rescue therapy, MTX concentrations are routinely monitored following administration of HD-MTX. The first time point when such measurement were performed differed from one to another DFCI protocol and MTX plasma levels at 24, 36 and 48 h following HD-MTX were available for 119, 255 and 208 patients, respectively, who were assessed for the relationship between MRP genotypes and EFS probabilities. The measurement of MTX plasma levels was performed by fluorescence polarization immunoassay (TDx Abbott Laboratories, Chicago, IL, USA) following the manufacturer's instructions.
Genotyping
Fourteen polymorphisms in MRP2, MRP3 and MRP5 genes located in regulatory and coding gene regions were selected from NCBI (National Center for Biotechnology Information) SNP (single-nucleotide polymorphism) databases (http:// www.ncbi.nlmnih.gov/SNP) ( Table 1 ). All selected polymorphisms were analyzed in 49 controls to estimate allele frequency, linkage disequilibrium (LD) and haplotype phase ( Figure 1 ). Selected tagSNPs (sufficient to define common haplotypes) with frequency X5% were subsequently genotyped in 273 ALL patients.
The MRP gene's polymorphisms were amplified by PCR, using 15-25 ng of genomic DNA obtained at remission. The sequence of forward and reverse primer pairs used for amplification of each SNP is outlined in Table 1 . PCR reactions were performed in a final volume of 25 ml using 0.4-0.6 mM of each of the primers, 0.1-0.15 mM of each of dNTPs, 1-2.5 mM MgCl 2 and 1.0 U of Taq polymerase (Platinum, Invitrogen, Burlington, ON, CA). For amplification of MRP2-993, MRP3-1696 and MRP5-1629 polymorphisms, 2, 6 and 2% of dimethylsulfoxide, respectively, was additionally added. Amplification was performed for 40 cycles composed of 30 s at 94 1C, 30 s at 59-68 1C, depending on the polymorphisms tested, and 30 s at 72 1C. The genotyping was performed by allele-specific oligonucleotide hybridization as described previously. 22 The sequence of allele-specific oligonucleotide probes specific for tested variants is given in Table 1 . The subset of samples was genotyped in duplicate to ensure genotype reproducibility. The amplification was not equally successful for all loci analyzed explaining the minor difference in the total number of genotypes.
Statistics
The estimates of LD, and haplotype phase in control individuals were obtained by PHASE software, version 2.0. 23 The tag SNPs were selected based on LD information (r 2 X0.94, Figure 1 ) using Haploview software (Daly Lab at the Broad Institute, Cambridge, MA, USA). Tag SNPs with the minor allele frequency X5% were retained for further analysis in ALL patients. Survival differences, estimated by Kaplan-Meier analysis for patients with different genotypes, were assessed using a log-rank test. Times to event, disease or a death were measured as the time between diagnosis and the event of interest; for censored cases, it corresponded to time between diagnosis and the study end-point (5-year post treatment, that is, 84 months after diagnosis) or to the September 2007. The hazard ratio (hazard ratio with a 95% confidence interval) for genetic variants was estimated by the Cox regression analysis, with and without inclusion of the common prognostic factors categorized according to relapse risk prediction (boys or girls; age below 1 year, 1-9.99 and above 10 years old; white blood cell below or above 50 Â 10 9 l -1 ; B-or T-cell type; DNA index above or below 1.16 and standard or high-risk group. 16 The type of DFCI treatment protocols (DFCI 87-01-DFCI 2000-01) was also entered in the multivariate analysis.
The frequency of hematological toxicity (based on the number of white blood cells and absolute neutrophil and platelet count) and hepatic toxicity (based on the aspartate aminotransferase and alanine transaminase levels) 21 were analyzed in relation to MRP genotypes. Toxicity grade 3 and 4 for each of above parameters were considered for the analysis except thrombocytopenia for which grade 2 was encountered as well. Between-group comparison was performed by Mann-Whitney test. Mann-Whitney was used to compare between genotypes log transformed values of MTX levels (mM) measured at 24, 36 and 48 h following HD-MTX. All analyses assessing the impact of genotypes/haplotypes were performed by SPSS statistical package (Chicago, IL, USA), version 17.0. A false discovery rate correction was performed to adjust for multiple comparisons using Q-value 
Abbreviations: ASO, allele-specific oligonucleotide; F, forward; MRP, multidrug resistance-related protein; R, reverse; SNP, single-nucleotide polymorphism. The base substitution that distinguishes the two variants of each polymorphism is given in bold for ASO probes. The number from SNP database (dbSNP) at National Center for Biotechnology Information is provided. Ancestral allele is given in bold and minor allele is underlined. The polymorphisms are presented as a change from ancestral to derived allele, unless ancestral allele is not known, when the change is given from major to minor allele SNPs leading to aminoÀacid substitutions are indicated.
software and bootstrap approach described in Storey et al.
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The P-value was estimated for false discovery rate level from 0.05 to 0.15.
Gene reporter assay and mRNA expression Haplotype-specific fragments corresponding to 1250 bp of MRP3 proximal promoter region upstream of transcription initiation site (5 0 flanking region) and encompassing À189 and À140 variants were amplified from genomic DNA of individual with known genotype. The region included a segment from À127 to À23-bp upstream from the translation initiation site that is important for MRP3 expression. 25 Fragments were cloned into the promoterless pGL3-basic vector (Promega, Madison, WI, USA). Constructs corresponding to three haplotypes were sequenced to confirm the presence of the expected polymorphic sites. Human placental Jeg-3, cervical cancer HeLa, and hepatoma HepG2 cell lines (American Type Culture Collection, Manassas, VA, USA) were co-transfected with 100 ng of firefly luciferase plasmid containing corresponding allelic construct and 0.5 ng of SV40-driven renilla luciferase pRL-SV40 plasmid to control transfection efficiency. Transfection was performed as previously described. 26 The renilla luciferase activity of the control pRL-SV40 was used to normalize the results of the firefly luciferase activity of the allelic constructs (relative luciferase activity was expressed as mean±s.d.). 26 Similar experiments were performed with empty pGL3-basic plasmid, presenting negative control. Each experiment was performed in triplicate and the difference between haplotypes in gene reporter activity was assessed by one-way analysis of variance with Bonferroni post hoc adjustment for number of pair-wise comparisons.
Results
Fourteen polymorphisms located in regulatory and coding regions of MRP2, MRP3 and MRP5 genes were selected from dbSNP database at NCBI. We initially genotyped these SNPs in 49 controls of Caucasian origin to estimate allelic frequency and determine haplotype phase. Minor allele frequency ranged from 5 to 49% (Figure 1 ) and genotype frequencies were in agreement with Hardy-Weinberg equilibrium. Organization of selected SNPs in haplotypes, along with the frequency in control population is given for each MRP gene in Figure 1 . The information on two MRP2 polymorphisms were captured by other SNPs, as based on coefficient of LD, R 2 X0.96, resulting in total of 12 tag MRP polymorphisms that were subsequently analyzed in patients. Association analysis of obtained genotypes with EFS probabilities showed that the carriers of MRP3 AÀ189 allele (AA and AT genotypes) had reduced EFS as compared with individuals with TT genotype (P ¼ 0.01, Figure 2a ). Owing to the LD (R 2 ¼ 79%) between the À1696 and À189 polymorphisms (Figure 1b ) similar association with EFS was noted for the carriers of MRP3 A-1696 allele (P ¼ 0.03, not shown). The haplotype *3 is uniquely tagged by the AÀ189 allele (AACG), whereas the AÀ1696 is shared between MRP3 haplotypes *3 and less common haplotype *5 (ATCG) (Figure 1b) . Accordingly, the same association with EFS was noted for haplotype *3. An association of MRP3 AÀ189 with EFS remained significant in multivariate analysis (hazard ratio ¼ 2.4, 95% confidence interval ¼ 1.2-4.7, P ¼ 0.01) with the inclusion of clinical prognostic factors in the model. It also remained significant after controlling for false discovery rate at level 0.05 for the number of polymorphisms tested (q ¼ 0.03). Similar association of the AÀ189 allele with disease-free survival and overall survival was found (P ¼ 0.02 and P ¼ 0.05, respectively, not shown). Further stratification according to the type of relapse revealed that the AÀ189 allele conferred four times higher risk of CNS relapse (univariate hazard ratio ¼ 3.7; 95% confidence interval ¼ 1.2-10.9; P ¼ 0.01, Figure 2a ) and was not affected in multivariate analysis. Isolated CNS relapse occurred in eight patients and in additional five patients it was accompanied by bone marrow relapse.
Given higher risk of an event associated with the MRP3 AÀ189 allele, it could have been hypothesized that it might as well affect MTX-related toxicity and/or MTX levels. The association of borderline significance (P ¼ 0.06) of AÀ189 allele with the less frequent occurrence of thrombocytopenia grade 2 was seen ( Figure 2b ). As the data on toxicity were available for 174 patients only, we also analyzed an association between MRP3 À189 polymorphism and EFS in this subgroup of patients. The association remained significant (P ¼ 0.007, not shown). And finally, the carriers of the AÀ189 allele had higher 24 h post-HD MTX levels when compared with patients with TT genotype (Figure 2b P ¼ 0.03) when the analyses were limited to the patients with an event only. The latter did not remain significant after correction for multiple testing (for the number of toxicity parameters and MTX levels tested). However, given the previous hypothesis emerging from AÀ189 association with lower EFS, these analyses should be rather regarded as additional confirmation of an association initially observed with EFS. Moreover, similar to the results obtained when the correlation with the event was analyzed, less frequent occurrence of thrombocytopenia grade 2 (P ¼ 0.04) and higher MTX levels (P ¼ 0.03) were also noted for the carriers AÀ1696 allele (not shown) that shares the same haplotype as AÀ189 variation.
No association between remaining MRP polymorphisms and MTX toxicity/MTX levels was obtained after correction for multiple testing (for the number of polymorphisms and number of outcomes).
We further performed gene reporter assay to define the functional significance of MRP3 À189 promoter variant and derived haplotypes. The promoter activity was tested in three different cell lines using the 1.2 kb promoter construct encompassing the À189 and À140 polymorphic sites ( Figure  2 ). The analysis were performed for three common haplotypes having at these positions TT, TC and AC alleles, corresponding to the promoter portion of common (45%) MRP3 haplotypes *1, *2 and *3 (Figure 1b) , respectively. The higher activity was noted for haplotype *2, as compared with haplotype *1 (Pp0.01, Figure 3 ). Haplotype *3 further increased promoter activity in Hela and HepG2 (Pp0.01, Figure 3 ).
Discussion
We identified MRP3-promoter AÀ189 T gene variation that may affect treatment responses in childhood ALL patients treated according to the DFCI protocols. The A allele conferred increased risk of event in childhood ALL patients, as shown in univariate and multivariate analysis. The same allele tended to have lower occurrence of toxicity, as shown by lower frequency of thrombocytopenia grade 2. This finding would be in accordance with drug-resistant phenotype usually thought to arise by an increased efflux and a decrease in cellular accumulation of anticancer drugs. Overexpression of MRP3 has been shown to result in high resistance to MTX in short-term drug exposure experiments. 5, 9, 12 Moreover, higher MRP3 mRNA levels in childhood ALL and acute myeloid leukemia patients were associated with a significantly worse disease prognosis. 27, 28 Indeed, our gene reporter assay showed that the haplotype tagged by MRP3 AÀ189 allele was associated with higher promoter activity.
Among patients that have had an event, the AÀ189 allele was also associated with higher MTX plasma levels 24 h following HD-MTX. This may suggest lower intracellular drug accumulation in accordance with Kool et al.
12 who found that the total amount of intracellular MTX was lower in the cells overexpressing MRP3. It should be kept however in mind that hepatobiliary clearance may as well affect MTX plasma concentration to the extent to which this route has a role in humans (recovery of MTX in the bile is o10% of the dose after intravenous administration). 12, 29 Indeed, recent experiments using MRP3 knock-out mice showed that plasma concentrations of MTX were significantly lower in MRP3 À/À mice than in wild-type mice caused by greater hepatic and biliary clearance. 29 Given high inter-individual variability in MRP3 expression, the polymorphic content of MRP3 gene has been extensively studied in different populations. 30, 31 The focus was mostly brought to the MRP3 C-211 T substitution because of the initial study, which found lower hepatic mRNA expression associated with T allele. 31 The position À211 refers to the translation initiation site and corresponds to À140 polymorphism in our study in which the position is given relative to the transcription initiation site. The TÀ211 (or TÀ140) allele was found to have adverse prognostic significance in acute myeloid leukemia 32 and lung cancer patients. 33 Subsequent functional analysis could not, however, confirm a change in reporter gene activity associated with this polymorphism 34 or mRNA levels in acute leukemia patients. 35 Our study did not reveal significant association of this polymorphism with treatment outcome or MTX levels. However, the reporter assay showed significantly lower promoter activity for haplotype *1 tagged by TÀ140 confirming the results of Lang et al. 31 The CÀ140 is present in both *2 and *3 haplotypes; haplotype *3 is distinguished from haplotype *2 by the presence of AÀ189 allele, which seems to further increase the promoter activity, at least in particular cell lines. Lang et al. 31 did not notice influence of the À189 polymorphism (position À260 in their study) on hepatic mRNA levels in healthy individuals, which may reflect the tissue-specific differences, lower sample size or differences between in vitro and in vivo data.
Several non-synonymous polymorphisms of which some were shown to have functional consequences have been identified in MRP3 gene. 30, 31 All except Arg1297His replace- ment appear with the frequency of minor allele o2% and were not examined here. The analysis of an association of MRP3 À189 polymorphism with the type of relapse showed that MRP3 AÀ189 effect is mostly limited to patients with CNS relapse. The therapy used for CNS prevention does not seem to confound this association. Six patients out of 48 that were carriers of AÀ189 allele had CNS relapse (Figure 2a) , of which 3 received chemotherapy only and 3 received chemotherapy with CRT for the CNS relapse prevention. Seven patients among 190 without AÀ189 allele had CNS relapse; four patients were treated with chemotherapy only and three were treated with combined IT and CRT treatment. It was previously reported that incidence of CNS relapse in SR boys was higher in patients that underwent treatment with DFCI 87-01. 20 We could not detect such an association in multivariate analysis because of the low number of patients with CNS relapse and those treated with DFCI 87-01 protocol (none of the patient with CNS relapse was treated with that protocol). It is thought that MRPs similar to P-glycoprotein may limit the drug uptake to CNS acting at the blood-brain and blood-cerebrospinal fluid barrier. 36 High expression of MRPs including MRP3 has been shown in brain tumors. 37, 38 Although several studies confirmed the expression of MRP1 and MRP5 at blood-brain barrier or blood-cerebrospinal fluid barrier, no clear evidence was provided for MRP2 and MRP3, 8, [39] [40] [41] until recently when Warren et al. 42 showed moderate expression of MRP3 in the brain, with at least a fourfold enrichment in microvessel endothelial capillary cells. This indicates that MRP3 expression likely has some role in blocking drugs to enter the brain. If an association of MRP3 AÀ189 allele with CNS relapse is confirmed it might have important consequences for upfront drug adjustment and CNS relapse prevention.
Several polymorphisms have been widely studied in MRP2 gene including 5 0 UTR C-24 T substitution and non-synonymous G1249A, T3563A and G4544A variations leading to Val417Ile, Val1188Glu and Cys1515Tyr amino-acid replacements, respectively. The TÀ24 seems to confer a decrease in gene expression, reporter gene activity and transporting capacity. 7, 43, 44 The association of this polymorphism with the clearance of mycophenolic acid in renal allograft recipients, diclofenac hepatotoxicity or response to irinotecan in non-small lung cancer patients was reported. [45] [46] [47] Rau et al. 48 found that the mean plasma MTX levels from 36 to 48 h after high drug dose were significantly higher in female ALL patients carrying the TÀ24 allele. We did not find such an association. Difference in MTX dose, treatment protocol or population studied might account for observed differences suggested that the some of pharmacogenetics findings cannot be necessarily extrapolated to other treatment protocols.
MRP2 Val417Ile was associated with an increased intestinal efflux and a significant decreased bioavailability of the b-blocker talinolol, 44, 49 in line with the observation of a higher gastrointestinal toxicity of MTX in African Americans treated for rheumatoid arthritis. 50 Val1188Glu and Cys1515Tyr correlated with higher mRNA and protein expression in liver 51 and with anthracycline-induced cardiotoxicity in non-Hodgkin lymphoma patients. 52 We did not find significant association of these polymorphisms with endpoints studied in our ALL patients.
Although several polymorphism have been identified in MRP5 gene, 53 less information is available whether these polymorphisms may affect the gene function or response to medication. 15 Dazert et al. 54 found no influence of MRP5 genetic variation on MRP5 mRNA expression in human heart. It appears that alternate splicing has a role in the regulation of MRP5 through the expression of a smaller, but potentially functional protein. 55 No association between studied MRP5 polymorphisms and ALL outcomes was found in this study.
In conclusion, we report an association of MRP3 AÀ189 T promoter variant with the treatment outcomes in childhood ALL. The AÀ189 allele correlated with poorer disease outcome, lower frequency of thrombocytopenia, increased promoter activity and higher post HD-MTX levels. This suggests a higher AÀ189 associated MTX efflux and consequently, lower drug sensitivity. The study provides additional information that will further increase the knowledge how to use host genetic variations to tailor therapy of anti-leukemia drugs.
